 "Natco launches hepatitis C drug Hepcinat LP in Nepal")
Natco Pharma Limited launched the first licensed generic version of ledipasvir & sofosbuvir combination in Nepal, under its brand name Hepcinat LP, on October 28, 2015.
Hepcinat LP is a two-drug fixed-dose combination product that contains 90 mg of ledipasvir and 400 mg of sofosbuvir in a single tablet, and sold globally by Gilead Sciences Inc, under its brand Harvoni.
It is indicated for the treatment of chronic hepatitis C genotype 1 infection in adults. Natco has priced its generic medicine, Hepcinat LP, at an MRP of Rs 25,000 for a bottle of 28 tablets in Nepal.
Hepcinat LP is a two-drug fixed-dose combination product that contains 90 mg of ledipasvir and 400 mg of sofosbuvir in a single tablet, and sold globally by Gilead Sciences Inc, under its brand Harvoni.
It is indicated for the treatment of chronic hepatitis C genotype 1 infection in adults. Natco has priced its generic medicine, Hepcinat LP, at an MRP of Rs 25,000 for a bottle of 28 tablets in Nepal.
Natco had signed a non-exclusive licensing agreement with Gilead Sciences earlier in 2015, to manufacture and sell generic versions of its chronic hepatitis C medicines, including generic version of Harvoni, in India and other 100 developing countries.